FibroBiologics received Nasdaq delisting determination for minimum bid price violation
FibroBiologics received a Staff Determination letter from Nasdaq on July 22, 2026, notifying the company that it had been determined to delist from The Nasdaq Capital Market due to failure to maintain a minimum bid price of $1.00 per share over 30 consecutive business days from June 8, 2026 through July 21, 2026. The company is ineligible for a standard 180-calendar day compliance period because it effected a reverse stock split within the prior one-year period. Securities are scheduled for delisting and suspension at market open on July 31, 2026 unless the company requests an appeal by July 29, 2026; the company stated its intention to request a hearing before a Nasdaq Hearings Panel.
- Nasdaq Staff Determination letter received July 22, 2026
- Bid price closed below $1.00 per share for 30 consecutive business days, June 8, 2026 through July 21, 2026
- Company ineligible for standard 180-calendar day compliance period due to reverse stock split within prior one-year period under Nasdaq Listing Rule 5810(c)(3)(A)(iv)
- Delisting scheduled and suspension at market open July 31, 2026 unless appeal requested by July 29, 2026
- Company intends to request hearing before Nasdaq Hearings Panel to appeal determination
FibroBiologics faces imminent suspension from Nasdaq trading unless it successfully appeals the delisting determination within one week; a prior reverse stock split eliminates the company's eligibility for the standard 180-day cure period.
Derived from 8-K filed 2026-07-24. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →